Mikhail Dvorkin

机构：Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center", Chungbuk National University Hospital

发表论文 81 篇 · 总被引 40029 次 · h-index 31

代表论文

• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study (2023 · The Lancet · 被引 704)
• Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer (2022 · JAMA · 被引 480)
• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Annals of Oncology · 被引 329)
• Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial (2022 · Nature Medicine · 被引 314)
• Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study (2022 · Annals of Oncology · 被引 151)
• Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial (2022 · Journal of Thoracic Oncology · 被引 111)